Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 99

Results For "adult"

1344 News Found

Zydus gets USFDA’s approval for Empagliflozin, Metformin Hydrochloride tablets
Drug Approval | July 12, 2022

Zydus gets USFDA’s approval for Empagliflozin, Metformin Hydrochloride tablets

Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.


India’s first homegrown mRNA COVID-19 vaccine likely to have low market penetration, says GlobalData
News | July 11, 2022

India’s first homegrown mRNA COVID-19 vaccine likely to have low market penetration, says GlobalData

Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small


Feeling younger can help us rehabilitate faster : Study
News | July 11, 2022

Feeling younger can help us rehabilitate faster : Study

Researchers from Bar-Ilan University find that even in old age, feeling young can lower the risks of developing physical disability and morbidity


Govt introduces 'Draft of New Drugs, Medical Devices and Cosmetics Bill, 2022'
Policy | July 11, 2022

Govt introduces 'Draft of New Drugs, Medical Devices and Cosmetics Bill, 2022'

The Bill aims to amend and consolidate the law relating to the import, manufacture, distribution and sale of drugs, medical devices and cosmetics


Glenmark launches Sitagliptin and its FDC at affordable price
News | July 08, 2022

Glenmark launches Sitagliptin and its FDC at affordable price

These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens


Sanofi flu vaccines licensed and approved for 2022-2023 influenza season
Drug Approval | July 05, 2022

Sanofi flu vaccines licensed and approved for 2022-2023 influenza season

Sanofi will begin to ship their vaccines helping to ensure more people will be immunized


Pfizer submits new drug application to the U.S. FDA for Paxlovid
Drug Approval | July 03, 2022

Pfizer submits new drug application to the U.S. FDA for Paxlovid

Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk


Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
News | July 01, 2022

Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia


Pfizer and BioNTech inks new agreement with US Government to provide additional doses of COVID-19 vaccine
News | June 30, 2022

Pfizer and BioNTech inks new agreement with US Government to provide additional doses of COVID-19 vaccine

105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses


Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions
Drug Approval | June 29, 2022

Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions

Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2